Table 2.
Clinicopathological characteristics of Greek and Yale NSCLC cohorts according to PD-L1 mRNA status
| Greek NSCLC cohort |
Yale NSCLC cohort |
|||||
|---|---|---|---|---|---|---|
| PD-L1 mRNA low | PD-L1 mRNA high | P-value | PD-L1 mRNA low | PD-L1 mRNA high | P-value | |
| Parameter | ||||||
| All patients | N =147 (46.8%) | N =167 (53.2%) | N=85 (49.2%) | N = 88 (50.8%) | ||
| Age (years) | P=0.1602 | P=0.1523 | ||||
| <70 | 101 | 126 | 51 | 45 | ||
| ≥70 | 38 | 31 | 24 | 36 | ||
| Unknown | 8 | 10 | 10 | 7 | ||
| Gender | P=0.9113 | P=0.3424 | ||||
| Female | 17 | 20 | 35 | 45 | ||
| Male | 122 | 138 | 42 | 38 | ||
| Unknown | 8 | 9 | 8 | 5 | ||
| Histology | P=0.2103 | P=0.3756 | ||||
| Adenocarcinoma | 58 | 53 | 55 | 53 | ||
| Squamous cell | 65 | 84 | 11 | 17 | ||
| Other | 16 | 20 | 9 | 11 | ||
| Unknown | 8 | 10 | 11 | 14 | ||
| Smoker | P=0.7697 | |||||
| Yes | 119 | 125 | NA | NA | ||
| No | 9 | 12 | NA | NA | ||
| Unknown | 19 | 30 | ||||
| Stage | P=0.2196 | P=0.6481 | ||||
| 1 | 44 | 50 | 36 | 40 | ||
| 2 | 32 | 48 | 11 | 14 | ||
| 3 | 45 | 45 | 19 | 13 | ||
| 4 | 16 | 12 | 5 | 9 | ||
| Unknown | 10 | 12 | 14 | 12 | ||
| Inflammation | P= 0.0002 | P= 0.001 | ||||
| 0–1 | 101 | 79 | 66 | 19 | ||
| 2–3 | 46 | 88 | 34 | 49 | ||
| Unknown | 0 | 0 | 0 | 5 | ||
P-values displayed in bold text reflect the presence of statistical significance (eg, P<0.05).